Literature DB >> 3857018

Pharmacokinetics of cefotiam in humans.

M C Rouan, J B Lecaillon, J Guibert, J Modai, J P Schoeller.   

Abstract

After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h. The 24-h urinary recovery was independent of the dose and averaged 53% of the dose. After intramuscular administration of 1 g of cefotiam to three healthy volunteers, a mean (+/- standard deviation) peak concentration of 16.6 +/- 5.1 micrograms/ml was reached at 0.75 to 1 h post dosing. The concurrent intramuscular administration of lidocaine and cefotiam did not modify the kinetics of cefotiam. During a constant-rate infusion, the steady-state plasma clearance decreased slightly when the infusion rate was increased. There was no trend towards accumulation of cefotiam in plasma during chronic treatment with 1 g intravenously every 12 h for 10 days.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857018      PMCID: PMC176233          DOI: 10.1128/AAC.27.2.177

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Pharmacokinetics of cefotiam in normal humans.

Authors:  F D Daschner; K A Hemmer; P Offermann; J Slanicka
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

2.  Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography.

Authors:  J B Lecaillon; M C Rouan; C Souppart; N Febvre; F Juge
Journal:  J Chromatogr       Date:  1982-03-12

3.  Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.

Authors:  M C Rouan; U Binswanger; F Bammatter; W Theobald; J P Schoeller; J Guibert
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

4.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

5.  Cefoperazone and cefotiam--two new cephalosporins: an in-vitro comparison.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1981-04       Impact factor: 5.790

  5 in total
  2 in total

1.  Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.

Authors:  K Chiba; M Tsuchiya; J Kato; K Ochi; Z Kawa; T Ishizaki
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.